Cancer

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as SMAD7, p12(DOC1/CDK2AP1), p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 14/October/2018, 12.12 am
Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as SMAD7, p12(DOC1/CDK2AP1), p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 14/October/2018, 12.12 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as HNF4α, CADM2, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/November/2018,11.20 pm
Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as HNF4α, CADM2, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/November/2018,11.20 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more

Probiotic-based therapy for Acute Myeloid Leukemia: Lactobacillus rhamnosus decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 12/August/2018, 10.40 pm
Probiotic-based therapy for Acute Myeloid Leukemia: Lactobacillus rhamnosus decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 12/August/2018, 10.40 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as FOXO1, CADM2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/November/2018, 8.01 pm
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as FOXO1, CADM2,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/November/2018, 8.01 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e…

read more

Probiotic-based anticancer therapy: Probiotic Lactobacillus Rhamnosus increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells, via up-regulation of its target gene, 12/November/2017, 7.41 pm
Probiotic-based anticancer therapy: Probiotic Lactobacillus Rhamnosus increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells, via up-regulation of its target gene, 12/November/2017, 7.41 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and…

read more

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm
Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more
Start Typing